---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-044372"
form_type: "8-K"
ticker: "NVAX"
cik: "0001000694"
company_name: "NOVAVAX INC"
filed_at: "2025-05-05T23:59:59+00:00"
generated_at: "2026-05-22T16:04:43.734115+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Novavax amends Takeda COVID vaccine pact; gets $19.5M upfront, tiered royalties

## Summary
- Upfront payment $19.5M from Takeda; $5M creditable against royalties for Takeda FY2024.
- Annual $2M service fee plus $8M milestone if Takeda gets marketing approval; $5M of milestone creditable.
- Profit share replaced with tiered royalty on net sales in mid-to-high teens, effective April 1, 2024.
- Takeda may develop a different vaccine strain but must procure it from Novavax.
- Parties also entered release agreement settling all claims related to original 2021 pact.

## SEC filing metadata
- accession: 0001104659-25-044372
- form_type: 8-K
- ticker: NVAX
- cik: 0001000694
- company_name: NOVAVAX INC
- filed_at: 2025-05-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1000694/000110465925044372/0001104659-25-044372-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1000694/000110465925044372/tm2513960d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-044372
- JSON: https://secwatch.observer/filing/0001104659-25-044372.json
- Plain text: https://secwatch.observer/filing/0001104659-25-044372.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.